Skin Infection Drug Requirements Eased in Final FDA Guidance

Clinical Trials Advisor
A A
While the FDA generally requires two Phase III trials to support approval of drugs to treat acute bacterial skin and skin structure infections (ABSSSI), an Oct. 16 final guidance says a single Phase III study that is supported by additional independent evidence may suffice.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00